Fatigue

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
Wednesday, February 14, 2024

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.

Infoblox's New AI-Powered SOC Insights Capability Reduces Critical Security Operations Challenges

Retrieved on: 
Wednesday, February 14, 2024

SOC Insights empowers security analysts to jump-start investigations that truly matter and dramatically reduce response time by turning vast amounts of security events, network, ecosystem, and unique DNS intelligence data into a manageable set of immediate, actionable insights at AI-speed.

Key Points: 
  • SOC Insights empowers security analysts to jump-start investigations that truly matter and dramatically reduce response time by turning vast amounts of security events, network, ecosystem, and unique DNS intelligence data into a manageable set of immediate, actionable insights at AI-speed.
  • Going beyond simple malware risk-based dashboards, SOC Insights enables cybersecurity teams to reduce mean-time-to-respond (MTTR) by eliminating wasted time by consolidating individual alerts into unique insights.
  • With SOC Insights, Managed Security Service Providers can help their customers improve their security posture, optimize their security investments, and streamline their operations.
  • For more information on SOC Insights and BloxOne Threat Defense capabilities, click here or contact an Infoblox representative.

Infoblox's New AI-Powered SOC Insights Capability Reduces Critical Security Operations Challenges

Retrieved on: 
Wednesday, February 14, 2024

SOC Insights empowers security analysts to jump-start investigations that truly matter and dramatically reduce response time by turning vast amounts of security events, network, ecosystem, and unique DNS intelligence data into a manageable set of immediate, actionable insights at AI-speed.

Key Points: 
  • SOC Insights empowers security analysts to jump-start investigations that truly matter and dramatically reduce response time by turning vast amounts of security events, network, ecosystem, and unique DNS intelligence data into a manageable set of immediate, actionable insights at AI-speed.
  • Going beyond simple malware risk-based dashboards, SOC Insights enables cybersecurity teams to reduce mean-time-to-respond (MTTR) by eliminating wasted time by consolidating individual alerts into unique insights.
  • With SOC Insights, Managed Security Service Providers can help their customers improve their security posture, optimize their security investments, and streamline their operations.
  • For more information on SOC Insights and BloxOne Threat Defense capabilities, click here or contact an Infoblox representative.

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Retrieved on: 
Wednesday, February 14, 2024

CHATHAM, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, held a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, and the path to file for FDA approval in the second half of 2024. The webinar was held on January 31, 2024 and hosted by Alliance Global Partners (A.G.P.).

Key Points: 
  • The webinar was held on January 31, 2024 and hosted by Alliance Global Partners (A.G.P.).
  • As previously announced, Tonix’s second positive Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for Tonmya™ for the management of fibromyalgia.
  • “We are now an important step closer to bringing a new, first-line treatment to fibromyalgia patients that offers broad symptom relief and favorable tolerability for chronic use and adherence.”

Think You May Be Stressed? Here are 3 Physical Signs of Chronic Stress from The Chicago School President, Dr. Michele Nealon, Psy.D.

Retrieved on: 
Tuesday, February 13, 2024

Finding ways to manage stress levels is critical to our mental and physiological health and wellness, according to Dr. Michele Nealon, a clinical psychologist, and President of the Chicago School.

Key Points: 
  • Finding ways to manage stress levels is critical to our mental and physiological health and wellness, according to Dr. Michele Nealon, a clinical psychologist, and President of the Chicago School.
  • Dr. Nealon has said, “Stress can cause major mental health challenges over time.
  • Specifically, chronic stress can lead to anxiety and depression and can also cause chronic health conditions such as high blood pressure, increased risk of stroke, and substance abuse challenges.
  • Rest assured that you are not alone in your battle with chronic stress, no matter how isolating it may feel.

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

Retrieved on: 
Tuesday, February 13, 2024

PARIS, FRANCE, 13 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as a first-line treatment in adults living with metastatic pancreatic adenocarcinoma (mPDAC).

Key Points: 
  • PARIS, FRANCE, 13 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as a first-line treatment in adults living with metastatic pancreatic adenocarcinoma (mPDAC).
  • This is the second approval for an Onivyde regimen in mPDAC, following the FDA’s approval in 2015 of Onivyde plus fluorouracil and leucovorin following disease progression with gemcitabine-based therapy.
  • “The results from the Phase III NAPOLI 3 trial represent the first positive data for an investigational regimen in first-line metastatic pancreatic adenocarcinoma versus the currently approved nab-paclitaxel and gemcitabine regimen," said Christelle Huguet, EVP and Head of Research and Development, Ipsen.
  • In the clinical trial, diarrhea was managed following institutional guidelines and appropriate antidiarrheal medications.9
    *NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Philadelphia hopes year-round schooling can catch kids up to grade level – will it make a difference?

Retrieved on: 
Tuesday, February 13, 2024

Upon becoming mayor of Philadelphia, Cherelle Parker announced that she will establish a working group on full-day and year-round schooling – an idea she had supported while campaigning.

Key Points: 
  • Upon becoming mayor of Philadelphia, Cherelle Parker announced that she will establish a working group on full-day and year-round schooling – an idea she had supported while campaigning.
  • The group will develop a strategy to keep Philadelphia public schools open for longer hours during the week, from 7:30 a.m. to 6 p.m., as well as over the summer, and to provide “meaningful, instructive out-of-school programming and job opportunities for students.” Below, education expert Daniel H. Robinson answers five questions about year-round schooling in Philadelphia.

What do we know about the mayor’s plan?

  • It does not state how many days or hours will be added to the 180 days Philadelphia currently requires.
  • For example, students might have 45 school days followed by 15 days of break, or 60 school days followed by 20 days of break.
  • The report suggested that the school year should be increased to 200 to 220 days.

How prevalent is year-round schooling?

  • Japan and Australia have school for almost the entire year, while the U.S. has school for only about nine months.
  • But they still maintain traditional school hours during the school year.
  • This three-year initiative involves 40 schools that will add 300 hours to their existing school calendar by having either longer days, longer school years or both.

Can the mayor legally do this?

  • The Philadelphia mayor can certainly extend the school day and the school hours since she appoints the school board members, who in turn control who is hired or fired as superintendent.
  • A more important question is: Should the mayor do this?
  • Despite the hope that longer school days or years will lead to gains in student achievement, there’s little evidence that they will.
  • A better evaluation plan would be to first solicit applications for the pilot program from the more than 200 Philadelphia schools.

What are the potential gains?

  • It makes it easier for them to drop off and pick up kids on their way to and from work.
  • It also provides kids a safe and supportive environment for more hours.
  • Keeping kids at school longer during the day and for more days during the year can lower juvenile crime.

What hurdles might year-round schooling face in Philly?

  • Many Philly public schools do not have adequate air conditioning to be open throughout the hot summer months.
  • More Philadelphia teachers are quitting or retiring than those who are being newly trained, according to the report.


Daniel H. Robinson does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
Tuesday, February 13, 2024

CHATHAM, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) --  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has engaged Rho, Inc. (Rho), a global contract research organization (CRO), to support Tonix’s preparation and planned submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia.

Key Points: 
  • “We intend to meet with the FDA in the first half of this year and to submit our NDA in the second half of the year.
  • In the study, Tonmya met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • “We are delighted in our continued support of Tonix and their Tonmya program,” said Tara Gladwell, President and COO at Rho.
  • “We are hopeful that this work may result in a new treatment for the millions of Americans that suffer from this debilitating, chronic disorder.”

ShiftKey Report Reveals Texas Healthcare Workers Make Frequent Personal Sacrifices

Retrieved on: 
Tuesday, February 13, 2024

DALLAS, Feb. 13, 2024 /PRNewswire/ -- ShiftKey, a leading technology marketplace disrupting healthcare through data and workforce empowerment, today released findings from its "Solutions to Healthcare Burnout Report," including insights from healthcare professionals in Texas - 96% of whom say working in the industry requires major personal sacrifices.

Key Points: 
  • DALLAS, Feb. 13, 2024 /PRNewswire/ -- ShiftKey , a leading technology marketplace disrupting healthcare through data and workforce empowerment, today released findings from its "Solutions to Healthcare Burnout Report," including insights from healthcare professionals in Texas - 96% of whom say working in the industry requires major personal sacrifices.
  • Through the report, ShiftKey explores how these sacrifices influence professionals' lives and their ability to address personal and professional needs and highlights how burnout impacts healthcare workers.
  • The report also reveals how independent working options can help alleviate these professionals' challenges, using insights directly from front-line workers.
  • Read the national report here: ShiftKey.com/Trends
    To stay updated on the latest news around ShiftKey, follow ShiftKey on LinkedIn , Instagram and Facebook .

ShiftKey's National Data Report Reveals Healthcare Workers Make Frequent Personal Sacrifices

Retrieved on: 
Tuesday, February 13, 2024

DALLAS, Feb. 13, 2024 /PRNewswire/ -- ShiftKey, a leading technology marketplace disrupting healthcare through data and workforce empowerment, today released findings from its "Solutions to Healthcare Burnout Report." To provide support and insights to healthcare workers ahead of National Caregivers Day, February 16, a day dedicated to recognizing the work of care professionals across the country, ShiftKey took a deep dive into the many sacrifices made by nurses influencing their lives and their ability to address personal and professional needs. Through the report, ShiftKey aims to uncover how burnout impacts healthcare workers and reveals solutions to alleviate these professionals' challenges.

Key Points: 
  • DALLAS, Feb. 13, 2024 /PRNewswire/ -- ShiftKey , a leading technology marketplace disrupting healthcare through data and workforce empowerment, today released findings from its "Solutions to Healthcare Burnout Report."
  • Through the report, ShiftKey aims to uncover how burnout impacts healthcare workers and reveals solutions to alleviate these professionals' challenges.
  • Most (91%) healthcare workers say their job is more demanding than the average American's, and 51% say it is much more demanding.
  • While burnout has been well documented in the healthcare field, there is little data on its impact on these professionals' personal lives.